Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales

Regeneron Pharmaceuticals Inc REGN earned $23.72 per share for Q4 FY21, more than double from $9.53 a year ago, beating the $18.11 estimate. 

  • Q4 sales almost doubled to $4.95 billion from $2.42 billion, surpassing the analysts' consensus of $4.47 billion, fueled by sales of COVID-19 treatment, REGEN-COV. 
  • Excluding REGEN-COV sales of $2.29 billion, sales increased 17% Y/Y. In Q4, the Company completed its final deliveries under its agreement with the U.S. government, delivering an additional 1.1 million doses of REGEN-COV.
  • Also See: Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use.
  • The Company said that given the lack of efficacy of REGEN-COV against the omicron variant, it is developing next-generation antibodies that are active against omicron and all other variants of concern.
  • Q4 U.S. Eylea sales increased 15% Y/Y to $1.55 billion. 
  • The operating income more than doubled to $2.64 billion. 
  • Guidance: For FY22, Regeneron sees an adjusted gross margin on product sales of 90%–92%. 
  • It expects R&D costs of $2.8 billion – $3 billion, with SG&A costs of $1.65 billion – $1.77 billion.
  • Price Action: REGN shares are up 0.69% at $625 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!